Navigation Links
Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer
Date:12/16/2008

BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr. An comes to Epitomics from Merck Research Laboratories, where he was Director of Biologics Research. He has over 12 years of experience in drug discovery and development in the biotech and pharmaceutical industries, focusing on therapeutic antibody discovery, humanization and affinity maturation, preclinical and clinical development.

Epitomics, exclusive maker of RabMAb(R) monoclonal antibodies, is the commercial supplier of rabbit monoclonal antibodies, with customers around the world, including major biotechnology/pharmaceutical companies and academic research laboratories. With several recently issued industry-changing patents, Epitomics has established its proprietary RabMAb as a unique antibody technology with an excellent IP position. The addition of Dr. An further sets the stage for Epitomics to move aggressively into the human antibody therapeutic market starting with major pre-clinical work on multiple targets in 2009.

"Dr. An brings a wealth of knowledge and experience in antibody discovery, which he will leverage with Epitomics' strong technologies and innovation to generate a pipeline of best-in-class antibody therapeutics focusing on clinically proven targets for broad therapeutic indications. We are delighted that he joins the executive management team at such a decisive stage of the company's development," said Dr. Guo-Liang Yu, CEO of Epitomics.

"RabMAb(R) is a novel class of monoclonal antibodies which possess unique biological properties, including ultra-high affinity, diversity in epitope recognition, and high target specificity. Epitomics provides me with the opportunity to expand the healthcare promises of biologics by developing RabMAb as a major therapeutic antibody discovery platform. We have embarked on a journey to bring truly widespread antibody therapy to patients around the world," said Dr. Zhiqiang An.

Prior to joining Epitomics, Dr. An played a major role in the creation of Merck's biologics research department including the establishment of their antibody technology platform. In his tenure at Merck, Dr. An and his team initiated a large number of antibody discovery programs in diverse therapeutics areas. As a result, multiple antibodies were identified as development candidates and are currently at various stages of development.

Dr. An started his biotech/pharmaceutical career at Millennium Pharmaceuticals where he established one of the very first programs attempting biocombinatorial natural products drug discovery using microbial molecular genetics and engineering approaches. Dr. An is a frequently invited speaker at scientific conferences and various academic settings and has authored numerous patents, journal articles, review papers, and books, including 2006's "Handbook of Industrial Mycology" and a comprehensive treatise entitled "Therapeutic Antibodies - from Theory to Practice," which will be published in early 2009. He received a B.S. in Biology from Shanxi Agricultural University, an M.S. in Biology from Beijing Agricultural University, and a Ph.D. in Plant Pathology from University of Kentucky, Lexington. Dr. An had his postdoctoral training at University of Wisconsin-Madison.

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb(R) (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc. (www.epitomics.com) is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , February 17, 2017 ... "Biomarkers Market by Product (Consumables, Service), Type (Safety, ... (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - ... market is projected to reach USD 53.34 Billion ... growing at a CAGR of 13.8% during the ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched ... the agricultural industry. Pilot studies are about to get under way for the framework, ... and 5G innovations. The concept is expected to be transferred eventually to other industries ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
(Date:2/16/2017)... DENVER , Feb. 16, 2017 UCHealth ... hospital to utilize LungDirect for pulmonary nodule patient management. ... a nodule, or a spot on the lung, UCHealth ... spent on manual data entry. Stephanie ... been tracking my nodule patients with an Excel spreadsheet, ...
Breaking Biology Technology:
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
(Date:1/19/2017)... Oregon and PUNE, India , January 19, 2017 ... Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," ... growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... owing to high-level security for both public and private sectors. ... ...
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
Breaking Biology News(10 mins):